Year: 2025

Luxembourg – 20 November 2025 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY, ISIN: LU0075646355, the Company) announced today results of Subsea7 Group (the Group, Subsea7) for the third quarter which ended 30 September 2025. Highlights Third quarter Adjusted EBITDA of $407 million, up 27% on the prior year period, equating to a margin of 22% Solid operational and financial performance from both Subsea and Conventional and Renewables, with Adjusted EBITDA margins of 24% and 17%, respectively Full year 2025 revenue is expected to be in a range between $6.9 and 7.1 billion while margins are expected to be between 20 and 21% Record high, quality backlog of $13.9 billion including $6.0 billion for execution in 2026 and $3.8 billion in 2027 Based on our firm backlog of contracts for execution in 2026, we expect revenue within a range of $7.0...

GUANGZHOU, China, Nov. 20, 2025 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2025. Recent Business UpdatesTherapy SelectionPresented study results at the Cell Reports Medicine on esophageal squamous cell carcinoma in September 2025. “Integrating ctDNA with clinical response evaluation improves residual disease detection post-neoadjuvant chemoradiotherapy to support organsparing strategies and that postoperative ctDNA stratifies recurrence risk beyond pathological response to inform adjuvant immunotherapy decisions”.Early DetectionPROMISE study test results presented at The Innovation...

Nilfisk CEO, Jon Sintorn, comments on Q3 2025 results: “In the third quarter of 2025, we continued to improve our cost structure and competitiveness to build resilience despite ongoing macroeconomic uncertainty. I was pleased to see growth in our Professional Business across all regions. Positively, EMEA delivered organic growth for the seventh consecutive quarter, and APAC achieved organic growth for the third consecutive quarter. Americas also grew in the quarter over a weak quarter same period last year. External headwinds, including tariffs and softer end-user demand, affected our margin. However, we maintained steady operational performance, reduced our cost, and improved free cash flow. A number of structural changes and decisions were executed in the quarter to improve our profitability and competitiveness. These changes and decisions...

Total revenues of €127.0 million compared to €116.6 million in the first nine months of 2024 Cash and cash equivalents of €143.5 million at end of September 2025 Financial flexibility enhanced with successful debt refinancing in October 20251 Lyme disease Phase 3 study VALOR on track Updated 2025 financial outlook confirmed1Saint-Herblain (France), November 20, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported consolidated financial results for the first nine months of the year, ended September 30, 2025. The condensed consolidated interim financial results are available on the Company’s website (Financial Reports – Valneva). Valneva will provide a live webcast of its nine-month 2025 results conference call beginning at 3 p.m. CET / 9 a.m. ET today. This webcast will also be available...